Fully biologically active when compared to standard. rHusTRAIL-R2 reduced the production of LPS-induced TNF by its ability to neutralize endogenous TRAIL in fresh human PBMC. In this assay, endogenous TRAIL is induced during a 24 hour exposure to LPS (10 ng/ml) but in the presence of rHusTRAIL-R2, TRAIL-induced TNF is suppressed.

TRAIL R2/DR5/TNFRSF10B Protein, Human, Recombinant is expressed in E. coli. The accession number is O14763.

Human

E. coli

ZTNFR9,Tumor necrosis factor receptor superfamily member 10B,TRICKB,TRICK2B,TRICK2A,TRICK2,TRAIL-R2,TRAILR2,TRAIL receptor 2,TNFRSF10B,TNF-related apoptosis-inducing ligand receptor 2,KILLER/DR5,KILLER,DR5,Death receptor 5,CD262

Glu52-Ser183

> 97% as determined by SDS-PAGE; > 97% as determined by HPLC

It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml.

Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Tumor necrosis factor-related apoptosis-inducing ligand Receptor 2 (TRAIL-R2) is a cell-surface receptor involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling.1 The death ligand TRAIL bears high potential as a new anticancer agent, as binding to the death receptors TRAIL-R1 or TRAIL-R2 triggers apoptosis in most cancer cells.2 TRAIL-R2 has been shown to be associated with a decrease in the survival rates of breast cancer patients.